Mural Oncology Pivots with $144.4M War Chest, Eyes Strategic Deals After Nemvaleukin Halt
DENVER, Colo., Apr 15, 2025 (247marketnews.com)- Mural Oncology (NASDAQ:MURA) stated that it’s halting all clinical development of nemvaleukin alfa and launching a high-stakes hunt for strategic alternatives to maximize shareholder value, backed by a hefty $144.4 million cash pile as of December 31, 2024.
Mural cut 90% of its workforce following its double blow: the Phase 2 ARTISTRY-6 trial in mucosal melanoma (92 patients, cohort 2) missed its primary endpoint after six months, while cohort 3’s less-frequent dosing in cutaneous melanoma showed lackluster activity. Paired with the Phase 3 ARTISTRY-7 interim survival flop in platinum-resistant ovarian cancer on March 25, nemvaleukin’s a no-go.
With $144.4 million in cash, cash equivalents, and securities, MURA’s got runway to play dealmaker; no firm offers or talks yet, but no timetable means flexibility.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (MURA)
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/15/25 12:00 PM
- MoBot’s Stock Market Highlights – 04/15/25 11:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/15/25 10:00 AM
- Today’s Top News and Trades- SKYE, KBLB, MTVA, ARBB, MURA, SNYR
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/15/25 08:00 AM